Hepatobiliary adverse drug reactions during treatment with olaparib: an analysis of data from the EudraVigilance reporting system
Further pharmacovigilance studies are needed to evaluate the hepatic safety profile of olaparib. Investigating the pathophysiological mechanisms underlying olaparib-induced liver injury could offer clinicians valuable insights for its prevention and management.
Authors
- Cecilia Cagnotta
- Antonietta Anatriello
- Maria Giuseppa Sullo (ORCID: https://orcid.org/0000-0001-9018-3573)
- Elena-Mirabela Velişcu
- Cristina Scavone
Institutions
- Inserm (FR)
- Regione Campania (IT)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Bordeaux Population Health (FR)
- University of Campania "Luigi Vanvitelli" (IT)
- Link Campus University (IT)
Publication Details
- Journal
- Frontiers in Drug Safety and Regulation
- Published
- 2026-01-09
- DOI
- https://doi.org/10.3389/fdsfr.2025.1736759
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 24.20